Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

89.32 +0.85 (+0.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 764,982
Open 88.47
Bid (Size) 86.20 (100)
Ask (Size) 104.00 (500)
Prev. Close 88.47
Today's Range 86.07 - 89.69
52wk Range 31.21 - 89.63
Shares Outstanding 56,367,802
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly
INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing... 
Via MarketMinute
News headline image
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million
From Apogee Therapeutics
Via GlobeNewswire

Performance

YTD
+17.9%
+17.9%
1 Month
+25.6%
+25.6%
3 Month
+13.1%
+13.1%
6 Month
+70.6%
+70.6%
1 Year
+168.4%
+168.4%

More News

Read More
News headline image
Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors ↗
Via The Motley Fool
Topics Regulatory Compliance
Apogee Therapeutics (NASDAQ:APGE) Reports Q4 2025 Results, Highlights Cash Runway and Key 2026 Clinical Catalysts ↗
Via Chartmill
News headline image
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Small-Cap Resilience: Russell 2000 Surges 3% as Geopolitical Tensions Ease and ‘Risk-On’ Appetite Returns
Via MarketMinute
Topics ETFs Economy Stocks
Gapping stocks in Monday's session ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
Via The Motley Fool
News headline image
What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Great Rotation: Small-Cap Stocks Slay the Giants as Market Breadth Hits Record Highs
Via MarketMinute
Topics Economy Initial Public Offering
News headline image
Apogee Therapeutics to Participate in Upcoming March Conferences
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Apogee Therapeutics, Inc. - Common Stock publicly traded?
Yes, Apogee Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Apogee Therapeutics, Inc. - Common Stock trade on?
Apogee Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Apogee Therapeutics, Inc. - Common Stock?
The ticker symbol for Apogee Therapeutics, Inc. - Common Stock is APGE on the Nasdaq Stock Market
What is the current price of Apogee Therapeutics, Inc. - Common Stock?
The current price of Apogee Therapeutics, Inc. - Common Stock is 89.32
When was Apogee Therapeutics, Inc. - Common Stock last traded?
The last trade of Apogee Therapeutics, Inc. - Common Stock was at 04/15/26 04:00 PM ET
What is the market capitalization of Apogee Therapeutics, Inc. - Common Stock?
The market capitalization of Apogee Therapeutics, Inc. - Common Stock is 5.03B
How many shares of Apogee Therapeutics, Inc. - Common Stock are outstanding?
Apogee Therapeutics, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.